← Back to patent-cliff list
ACCG-2671
Tier C — Watch / tradeACCG-2671
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Amylin Receptor, CT-R
Indications (approved)：Obesity
Regional status
US
Phase II
2025-12-29
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ACCG-2671?
Approved indications include: Obesity.
When does the ACCG-2671 patent expire?
No public expiry year is available for ACCG-2671 yet; this page updates once verified.
How do I get a quote for ACCG-2671 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29